Checkpoint Therapeutics Overview

  • Founded
  • 2014

Founded
  • Status
  • Public

  • Employees
  • 18

Employees
  • Stock Symbol
  • CKPT

Stock Symbol
  • Investments
  • 1

  • Share Price
  • $3.82

  • (As of Monday Closing)

Checkpoint Therapeutics General Information

Description

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 95 Sawyer Road
  • Suite 110
  • Waltham, MA 02453
  • United States
+1 (781) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Checkpoint Therapeutics Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.82 $3.72 $3.45 - $19.00 $42.5M 11.4M 211K -$8.70

Checkpoint Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 65,310 200,331 137,862 79,166
Revenue 134 268 1,069 1,708
EBITDA (71,459) (56,723) (23,201) (24,850)
Net Income (71,358) (56,670) (23,081) (24,714)
Total Assets 21,620 55,728 42,596 26,966
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Checkpoint Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Checkpoint Therapeutics‘s full profile, request access.

Request a free trial

Checkpoint Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisiti
Biotechnology
Waltham, MA
18 As of 2022
00000
00000000000 00000

00000

nim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea comm
0000000000000
Thousand Oaks, CA
00000 As of 0000
00.000
000000000000 00.000

000000

irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nul
0000 000000000
Hennigsdorf, Germany
00 As of 0000
000.00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Checkpoint Therapeutics Competitors (26)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Amgen Formerly PE-Backed Thousand Oaks, CA 00000 00.000 000000000000 00.000
000000000 00000000 Venture Capital-Backed Hennigsdorf, Germany 00 000.00 0000000000 0 000.00
000000 Formerly VC-backed Wilmington, DE 0000 00000000000
000000 00000000000 Corporation New York, NY 00 00000 000000000 00000
000000 00000000000 Venture Capital-Backed New York, NY 000.00 00000000000 000.00
You’re viewing 5 of 26 competitors. Get the full list »

Checkpoint Therapeutics Patents

Checkpoint Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2017290709-A1 Pd-l1-specific antibodies and methods of using the same Pending 29-Jun-2016 00000000000
CA-3027204-A1 Pd-l1-specific antibodies and methods of using the same Pending 29-Jun-2016 00000000000
EP-3478723-A2 Pd-l1-specific antibodies and methods of using the same Pending 29-Jun-2016 00000000000
EP-3478723-A4 Pd-l1-specific antibodies and methods of using the same Pending 29-Jun-2016 00000000000 0
JP-2022120008-A Pd-l1-specific antibody and method of using the same Pending 29-Jun-2016 C07K16/2827
To view Checkpoint Therapeutics’s complete patent history, request access »

Checkpoint Therapeutics Executive Team (3)

Name Title Board Seat Contact Info
James Oliviero III Chief Executive Officer & Board Member
Garrett Gray Chief Financial Officer
You’re viewing 2 of 3 executive team members. Get the full list »

Checkpoint Therapeutics Board Members (3)

Name Representing Role Since
00000 00000000 000 Checkpoint Therapeutics Chief Executive Officer & Board Member 000 0000
0000000 00000 00 Self Chairman & Board Member 000 0000
0000 0000000000 Self Board Member 000 0000
To view Checkpoint Therapeutics’s complete board members history, request access »

Checkpoint Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Checkpoint Therapeutics Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 (00 000000000 Buildings and Property
To view Checkpoint Therapeutics’s complete investments history, request access »

Checkpoint Therapeutics ESG

Risk Overview

Risk Rating

Updated April, 01, 2021

47.19 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

0.000

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 14,042

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 947

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 452

Rank

00.00

Percentile

To view Checkpoint Therapeutics’s complete esg history, request access »